Navigation Links
TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
Date:10/10/2008

PLEASANTON, Calif., Oct. 10 /PRNewswire/ -- TriReme Medical Inc. (TMI) announced today that it has been authorized to affix the CE (Conformite Europeenne) marking and commercialize in Europe the Antares(TM) Coronary Stent System, a unique main vessel stent system specially designed for use at or near coronary bifurcations.

Representing the next generation in bifurcation stenting, the Antares(TM) system has potential use in a quarter of the 2.2 million angioplasty procedures performed annually worldwide. Antares(TM) stents are not yet approved in the United States and are limited by Federal law to investigational use.

"We are very pleased to achieve this significant milestone that allows commercialization of our Antares(TM) stent system in Europe," said Eitan Konstantino, PhD, President and Chief Executive Officer of TMI. "We believe that the Antares(TM) stent system represents a breakthrough in the treatment of patients suffering from coronary artery disease at or near bifurcations.

"I like the Antares(TM) system concept. The system is designed to fit all classes of bifurcation lesions, irrespective of the size and angulation of the side-branch," said Professor Carlo Di Mario from Royal Brompton Hospital in London. "The operator does not need to commit to a pre-determined side branch treatment and has the flexibility to do what is right for the patient."

Lesions at or near side branches in the coronary tree pose multiple challenges to interventional cardiologists. Combining a low profile stent with a proprietary delivery system, the Antares(TM) system provides a unique set of solutions to the challenges of bifurcation stenting. It can be delivered and deployed in a single step while maintaining access to the side branch and scaffolding the ostium, or the origin of the side branch. As a result, the cardiologist has greater flexibility of treatment options, with the freedom to deploy a second stent in the side branch when additional support is necessary.

"The Antares(TM) stent system is an elegant solution to treat bifurcation lesions that is focused on the main vessel," observed Alexandre Abizaid, MD, PhD, Chief of Coronary Interventions at the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid continued, "It increases operators' confidence by providing continuous side branch access throughout the procedure."

About TriReme Medical Inc.

TriReme Medical Inc. (TMI) is a privately held medical device company backed by Three Arch Partners and Adams Street Partners. TMI is based in California and dedicated to the development and manufacturing of novel stent technology for the treatment of atherosclerotic disease at or near bifurcations.


'/>"/>
SOURCE TriReme Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today ... be presenting at two upcoming investor conferences: SeeThru ... Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James ... Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the ... founder of Retina Group of New York , is a Board Certified ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
Breaking Medicine News(10 mins):